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Abstract
Glucose is the main and preferred source of energy for mammalian cells. Mammalian 
cells need glucose constantly. Long-lasting disturbances in blood glucose concentrations 
can cause diseases and death. Therefore, blood glucose concentrations must be within 
narrow limits. The process of maintaining blood glucose at a steady-state level is called 
glucose homeostasis.
Keywords: glucose homeostasis, glucose metabolism, pancreas, liver, kidney, 
hypothalamic-pituitary axis
1. Introduction
Carbohydrates play several roles in the metabolic processes and as structural elements of 
living organisms. An essential substrate for all mammalian cells is monosaccharide, glucose. 
In human glucose is obtained directly from the diet or by synthesis in the liver and kid-
ney. Monosaccharides are transported across the intestinal wall to the portal vein and then to 
liver cells and other tissues. Monosaccharides play a role as a precursor of fatty acids, amino 
acids, and glycogen. They are also oxidized by the various catabolic pathways of cells, play 
an important role in the synthesis of pentose sugars for DNA and RNA, as well as generate 
NADPH + H+ for the synthesis of lipids.
2. Transport of monosaccharides into cells
In the first step of carbohydrate metabolism, monosaccharides are transported across the 
plasma membranes. Due to hydrophilic nature of glucose and other monosaccharides, 
the lipid bilayer of plasma membrane is impermeable for these substances. Therefore, 
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monosaccharide transport across the plasma membrane is mediated via membrane trans-
port proteins called glucose transporters.
In human, there are three classes of glucose transporters: the facilitative glucose transport-
ers, the sodium-glucose cotransporters, and SWEETs. However, these transporters are named 
“glucose transporters”; they transport not only glucose but also other substances such as fruc-
tose, fucose, xylose, vitamins, ions, etc. GLUT1 was also suggested to be receptor for human 
T-lymphotropic virus (HTLV) and plays an essential role in CD4 T-cell activation
2.1. The GLUT family
GLUT proteins are encoded by the SLC2 genes. These proteins are members of the major 
facilitator superfamily (MFS) of membrane transporters. These transporters are uniporters. 
They facilitate the diffusion of substrates across cellular membranes along a concentration 
gradient [1, 2]. The GLUT family comprises 14 isoforms GLUT1–GLUT12, GLUT14, and 
HMIT (GLUT13). HMIT is the proton-driven myoinositol transporter.
The human GLUT proteins are comprised of about 500 amino acid residues. They are pre-
dicted to possess 12 transmembrane-spanning α-helices and a single N-linked oligosaccharide 
[4]. The cytoplasmic domain contains a short N-terminal segment, a large intracellular loop 
between transmembrane domains 6 and 7, and a large C-terminal segment. The sequences 
among members of family are 14–63% identical and 30–79% conservative [5]. Sequence align-
ments of all members reveal several highly conserved structures [5]. The fact that the trans-
membrane domain primary structure is largely conserved suggests that the glucose channel is 
basically identical in structure among the members of this family [6]. One or more GLUT pro-
teins are expressed in every cell type of the human body. It is highly likely that the major 
substrates for several GLUT proteins have not yet been identified [3].
2.2. The Na+/glucose cotransporters
Sodium-glucose transporters, also known as Na+/glucose cotransporters or symporters, are 
encoded by SLC5 genes. These transporters are members of a larger gene family of sodium/
substrate symporter family (SSSF) that contain a common SSF motif in the fifth transmem-
brane region [7]. There are 12 human genes in the SLC5 family that are expressed in dif-
ferent tissues. These cotransporters transport substrates via a secondary active transport 
mechanism. SGLTs do not directly utilize ATP to transport glucose against its concentra-
tion gradient; rather, they must rely on the sodium concentration gradient generated by the 
sodium-potassium ATPase as a source of chemical potential [8]. The Na+-electrochemical 
gradient provided by the Na+-K+ ATPase pump is utilized to transport substrate into cells 
against its concentration gradient. Except for SGLT3 which is glucose sensor, all are sodium 
cotransporters [9]. The function of ten are tightly coupled plasma membrane Na+/substrate 
cotransporters for different solutes, one is a Na+/Cl−/Choline cotransporter and one is a glu-
cose-activated ion channel [7].
All members of the SLC5 family code for 60 to 80 kDa proteins contain 580–718 amino acids 
[10]. The genes SLC5 contain 14–15 exons; however, SLC5A7 gene contains 8 exons, and 
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SLC5A3 gene contains 1 exon [7]. SGLTs contain 14 transmembrane α-helices (TMH) with 
both NH
2
 terminus and the COOH terminus facing the extracellular (luminal) side of the 
cell [11, 12]. The human sodium cotransporters share an amino acid identity of 21–70%. The 
transporter contains a single glycosylation site [11]. Of note, glycosylation is not required for 
functioning of the protein. Phosphorylation sites are suggested between transmembrane heli-
ces 5 and 6 [13] and between transmembrane helices 8 and 9 [14].
2.3. The SWEET proteins
Sugar efflux transporters are essential for the maintenance of human blood glucose levels. 
In mammals, glucose efflux from the liver is crucial for the maintenance of blood glucose 
levels. Chen et al. [15] identified a new class of sugar transporters, named SWEETs. The 
SWEETs are ubiquitously expressed in plant. SWEET belongs to a novel transporter fam-
ily with 17 members in Arabidopsis and 21 in rice [15]. Homologs of SWEETs have also been 
identified in humans (SWEET1) [15]. Although human and animal genomes typically con-
tain only a single SWEET gene, a major exception is Caenorhabditis elegans, which contains 
seven SWEET paralogs [16]. SWEET is a glucose uniporter.
The human SWEET1 is expressed in the oviduct, epididymis, intestine, and β-cell lines [15]. 
It is a candidate for the vesicular efflux from enterocytes, hepatocytes, and β cells [15]. The 
SWEET class of transporters is predicted to have seven transmembrane helices. Eukaryotic 
SWEETs have a predicted topology comprising a repeat of three membrane-spanning domains 
that are connected by an inversion linker helix with extracellular N-terminus and intracellu-
lar C-terminus [15–17]. Cytosolic C-terminus of the SWEETs is very long and may serve as a 
docking platform for protein interactions [18]. C-termini show much less conservation and 
are characterized by extensive length variability [19].
3. General information on glucose metabolism
3.1. Glucose as a source of cellular energy
When energy is needed, glucose is rapidly metabolized to produce adenosine triphosphate 
(ATP), a high-energy product. Glucose is oxidized through a long series of reactions that 
extract the great amount of possible energy from it.
3.1.1. Glycolysis
The first which begins the complete oxidation of glucose is called glycolysis (or Embden-
Meyerhof-Parnas pathway). It is an anaerobic process. During glycolysis, each glucose mol-
ecule is split and converted to two three-carbon units. The next result of glycolysis is the 
production of two pyruvate molecules, two ATP, and two NADH + H+. During glycolysis, the 
cell receives about 5% of the total energy available. In the presence of oxygen, aerobic organ-
isms oxidize pyruvate to CO
2
 and H
2
O. In the absence of oxygen, pyruvate can be converted 
to several types of reduced molecules, such as ethanol (e.g., yeast) or lactate (e.g., muscle cells, 
red blood cells). This anaerobic process is referred to as fermentation.
Glucose Homeostasis
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3.1.2. Oxidative decarboxylation
During aerobic metabolism of glucose, pyruvate is transported inside mitochondria, where is 
oxidized. Oxidation of pyruvate to acetyl coenzyme A (Acetyl-CoA) produces two molecules 
of CO
2
 and NADH + H+.
3.1.3. Krebs cycle
Further series of reactions is collectively called “Krebs cycle,” also known as the “citric acid 
cycle” or the “tricarboxylic acid cycle (TAC).” Through a series of reactions in mitochondria, 
acetyl-CoA is oxidized to CO
2
. Fuel for the Krebs cycle comes also from lipids (fats) and pro-
teins (amino acids), which produce the molecule acetyl-CoA. If carbohydrates are the fuel for 
Krebs cycle, this cycle occurs twice since each glucose produces two pyruvates and then in the 
process of oxidative decarboxylation two molecules of acetyl-CoA.
3.1.4. Electron transport chain
The oxidative phosphorylation, which occurs in mitochondria, is a series of reactions that 
utilize the energy from NADH + H+ and FADH
2
. The electrons are successively passed down 
the chain of cytochromes, each time releasing some of their energy, which is then used to 
pump protons actively across the membrane into the matrix down this chemiosmotic gradi-
ent but can only do so through the ATP synthase. The result of the electron transport chain is 
three molecules of ATP, if a donor of protons and electrons is NADH + H+ and one molecule 
of H
2
O. In the case of FADH
2
, the result of this process is two molecules of ATP and one 
molecule of H
2
O.
3.2. Glycogenesis
Glycogenesis is the process of glycogen synthesis from glucose. Glycogen is the storage form 
of glucose. Glycogenesis occurs after a meal, when blood glucose levels are high. All cells 
contain glycogen, but most is stored in liver cells (about 90 g in a 70-kg man) and muscle cells 
(about 350 g in a 70-kg man). In this process, glucose molecules are added to chains of glyco-
gen for storage in mentioned organs.
Glucose-6-phosphate is converted to glucose-1-phosphate by phosphomutase. Sugar-
nucleotide synthesis is a reaction preceding sugar polymerization processes. Uridine 
diphosphate glucose (UDP-glucose) is more reactive than glucose. By itself, this is a read-
ily reversible reaction; however, the subsequent hydrolysis of pyrophosphate to two inor-
ganic phosphates (PPi) will readily occur, and this will drive the reaction over the product 
side.
For the synthesis of glycogen, the starting point is the protein glycogenin. If the chain contains 
more than ten molecules of glucose residues, it acts as a primer for proglycogen synthase 
which elongates primer. The elongation is due to the addition of new glucose molecules to 
the existing chain.
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3.3. Glycogenolysis
When the blood sugar levels fall, glycogen stored in the muscle and liver may be broken 
down. This process is called glycogenolysis. The liver can consume glucose-6-phosphate 
in glycolysis and can also remove the phosphate group using the enzyme glucose-6-phos-
phatase and release the free glucose into the bloodstream. Since muscle cells lack glucose-
6-phosphatase, they cannot convert glucose-6-phosphate into glucose and therefore use the 
glucose-6-phosphate to generate energy for muscle contraction.
3.4. Gluconeogenesis
Gluconeogenesis generates glucose from noncarbohydrate precursors such as lactate, glyc-
erol, pyruvate, and glucogenic amino acids. It occurs primarily in the liver. Under certain 
conditions, such as metabolic acidosis or starvation, the kidney can make small amounts of 
new glucose. When liver glycogen is depleted, the gluconeogenesis pathway provides the 
body with adequate glucose. The major substrates for gluconeogenesis are lactate (formed in 
muscle and red blood cells), amino acids (derived from the muscle), and glycerol (produced 
from the degradation of triacylglycerols). During anaerobic glycolysis, pyruvate is reduced 
to lactate. Lactate is released to the bloodstream and transported into the liver. In the liver 
lactate is converted to glucose, and then glucose is returned to the blood for use by the 
muscle as an energy source. This cycle is termed the Cori cycle. The gluconeogenesis of the 
cycle is a net consumer energy, costing the body four molecules of ATP more than are pro-
duced during glycolysis. The reaction sequence in gluconeogenesis is largely the reverse of 
glycolysis.
Of all the amino acids that can be converted to glycolytic intermediates, alanine is perhaps the 
most important. When the muscle produces large quantities of pyruvate, for example, during 
exercise, some of these molecules are converted to alanine. Alanine is transported to the liver, 
reconverted to pyruvate and then to glucose. This cycle is termed the glucose-alanine cycle. 
The glucose-alanine cycle plays a role in recycling α-keto acids between the muscle and liver 
as well as is a mechanism for transporting amino nitrogen to the liver (the muscle cannot 
synthesize urea from amino nitrogen).
3.5. The pentose phosphate pathway
The pentose phosphate pathway is primarily a cytoplasmic anabolic pathway which converts 
the six carbons of glucose to five carbon sugars and reducing equivalents. Its principal prod-
ucts are NADPH + H+, for reductive biosynthesis reactions within cells, and ribose-5-phos-
phate, for synthesis of the nucleotides and nucleic acids.
The pentose phosphate pathway occurs in the cytoplasm and is an alternative to glycolysis. 
There are two distinct phases in the pathway. The first is the oxidative phase. In this phase, 
two molecules of NADP+ are reduced to NADPH + H+, utilizing the energy from the conver-
sion of glucose-6-phosphate into ribose-5-phosphate. The nonoxidative phase of the pathway 
primarily generates ribose-5-phosphate. This pathway also converts five carbon sugars into 
Glucose Homeostasis
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both six (fructose-6-phosphate) and three (glyceraldehyde-3-phosphate) carbon sugars which 
can then be utilized by the pathway of glycolysis.
4. Role of the pancreas in the glucose homeostasis
The pancreas plays a key role in the glucose homeostasis. The endocrine and exocrine pan-
creas has a complex anatomical and functional interaction [20]. Glucose metabolism is highly 
dependent on hormones secreted by the islets of Langerhans [21]. To avoid postprandial 
hyperglycemia and fasting hypoglycemia, the body can adjust glucose levels by secreting 
two hormones: insulin and glucagon. These hormones work in opposition to each other [22]. 
There are four major cell types in the pancreatic islets of Langerhans: the β-cells that secrete 
insulin and amylin, α-cells secrete glucagon, δ-cells secrete somatostatin, and PP cells secrete 
pancreatic polypeptide (PPY) [22, 23].
4.1. Insulin
Insulin secretion depends on the circulating glucose concentrations. It is secreted if the blood 
glucose concentration is ≥ 3 mmol/L [24]. Increased circulating glucose levels > 5 mmol/L 
results in increase of output of insulin and C peptide by the β-cells. Postprandially, the 
secretion of insulin occurs in two phases [26]. Long-term release of insulin occurs if glucose 
concentrations remain high [25]. Insulin secretion needs at least two signaling pathways, 
the K
ATP
 channel dependent and K
ATP
 channel independent, respectively [27, 28]. Glucose 
enters β-cells via GLUT2, which is believed to play a role in glucose-stimulated insulin 
secretion.
Insulin regulates glucose homeostasis at many sites, as for example, reducing hepatic glucose 
output (via decreased glucogenesis and glycogenolysis), inducing a process of glycogenesis 
(liver, muscle), and increasing the rate of glucose uptake, primarily into striated muscle and 
adipocytes. In most nonhepatic tissues, insulin increases glucose uptake by increasing the 
number of plasma membrane GLUT1 and GLUT4.
4.2. Glucagon
Glucagon is a hormone which is secreted by α-cells in response to hypoglycemia. It acts 
as the counter-regulatory hormone to insulin. Pancreatic α-cells contain a special set of 
channels that generate action potentials of Na+ and Ca2+ in the absence or at low levels of 
glucose [29].
Glucagon activates glucose formation and release from the liver to stabilize blood glucose 
[30]. Glucagon stimulates gluconeogenesis and glycogenolysis and decreases glycogenesis 
and glycolysis. It also stimulates gluconeogenesis by stimulation of uptake of amino acids 
in the liver and increases the release of glycerol from adipose tissue which can further 
be used in the liver during gluconeogenesis [31]. An elevated glucagon-to-insulin ratio 
accelerates gluconeogenesis as well as fatty acid β-oxidation and ketone bodies formation 
[30, 32].
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4.3. Somatostatin
Somatostatin is secreted by many tissues, including pancreatic δ-cells, intestinal tract, and 
central nervous system. It is released in response to glucose at lower concentrations than 
β-cells [33]. Somatostatin is a potent local inhibitor adjacent β- and α-cells [34]. Somatostatin 
release is increased in response to glucose stimulation [35, 36] and is Ca2+ dependent [36]. 
Acute administration of somatostatin to animals reduces food intake [37, 38]. Somatostatin 
has been reported to have no direct effect on basal glucose production (gluconeogenesis or 
glycogenesis) in isolated hepatocytes [39], and in vivo it does not alter the basal glucose pro-
duction rate when the levels of insulin and glucagon are maintained [39, 40]. The portal vein 
insulin and glucagon levels were significantly decreased by somatostatin infusion [40].
4.4. Amylin
Amylin is produced by β-cells and stored in their secretory granules. It is co-secreted with 
insulin from pancreatic β-cells in response to glucose as same as insulin [41], in a roughly 
about 1:10 amylin/insulin ratio [42]. Plasma amylin levels are low during fasting and increase 
during meals and following glucose administration, and the levels are directly proportional 
to body fat [42]. Amylin participates in glucose homeostasis by two mechanisms: retarding 
gastric emptying in dose-response manner [43] and suppressing postprandial glucagon secre-
tion [43, 44]. There is also evidence that amylin functions as an adiposity signal in addition to 
a satiety signal.
4.5. Pancreatic polypeptide (PPY)
The pancreatic polypeptide (PP) is produced predominantly by F cells (PP cells). Circulating 
PP concentrations increase following nutrient ingestion in a biphasic manner in proportion 
to the caloric load [45]. The secretion of PP during meals requires an intact vagus nerve. 
Pancreatic polypeptide affects metabolic functions including glycogenolysis and decreases 
fatty acid levels [46]. It also inhibits pancreatic secretion.
5. Role of the liver in the glucose homeostasis
The liver plays a major role in blood glucose homeostasis by maintaining a balance between 
the uptake and storage of glucose via glycogenolysis and gluconeogenesis. The liver is the pri-
mary organ for glucose metabolism. About 90% of all circulating glucose not derived directly 
from the diet comes from the liver. Hepatocytes take up glucose by GLUT2 in the presence 
of high concentrations of glucose. In hepatocytes, glucose is phosphorylated by glucokinase 
to glucose-6-phosphate. From glucose-6-phosphate, the glucose is directed into glycogenesis, 
the pentose phosphate pathway, or glycolysis.
In response to ingestion of glucose and the resulting hyperinsulinemia and hyperglycemia, 
the fasting liver shifts from net output to net uptake of glucose. Healthy human adults ingest-
ing 75 g glucose exhibited peak plasma glucose and insulin concentrations of 7.8 mmol/L and 
325 pmol/L, respectively [47]. Key enzymes in opposing metabolic pathways, glycolysis, and 
Glucose Homeostasis
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glycogenesis must be regulated for net flux in the appropriate direction to be achieved. The 
net glucose release is the result of two simultaneously ongoing pathways that are tightly regu-
lated. Two enzymes specific for gluconeogenesis are opposed to the glycolytic enzymes. These 
enzymes regulate substrate cycles between gluconeogenesis and glycolysis. Glycogenolysis 
occurs within 2–6 hours after a meal in humans, and gluconeogenesis has a greater impor-
tance with prolonged fasting [48].
The rate of gluconeogenesis is controlled principally by the activation of gluconeogenic enzyme 
genes that are controlled by glucagon, glucocorticoids, and the interleukin-6 family of cytokines 
[48]. Insulin decreases gluconeogenesis by suppressing the expression of phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase, and glucagon and glucocorticoids stimulate glucose 
production by inducing these genes [49]. Glucagon is a regulator of hepatic glucose production 
during fasting, exercise, and hypoglycemia. It also plays a role in limiting hepatic glucose uptake. 
In response to a physiological rise in glucagon, hepatic glucose production is rapidly stimulated. 
This increase in hepatic glucose production is due to an enhancement of glycogenolysis, with lit-
tle, or no, acute effect on gluconeogenesis [50]. The liver can release of glucose into the circulation. 
The skeletal muscle releases lactate, from where it can shuttle back to the liver (the Cori cycle).
The newborn mammals are in a transitional state of glucose homeostasis [51]. The diet of 
neonate is a low-carbohydrate, high-fat milk diet. The neonate must oxidize the stored liver 
glycogen, which is synthesized in the final days of gestation [51]. The initiation of hepatic gly-
cogenolysis and gluconeogenesis in the first postnatal hours is critical for the maintenance of 
glucose homeostasis at this time [52]. Fetal life is characterized by chronic hyperinsulinemia. 
At birth hyperinsulinemia continues briefly and is one of the factors involved in the natural 
delay in hepatic glycogenolysis [53]. Counter-regulatory hormone actions are vital for the 
reversal of the postnatal hypoglycemia and for establishing glucose homeostasis at this time. 
Glucagon released in response to the postnatal hypoglycemia is responsible for initiation gly-
cogenolysis and switching on hepatic gluconeogenesis [52].
6. Role of the kidneys in the glucose homeostasis
The human kidney is involved in the regulation of glucose homeostasis via three mechanisms: 
release of glucose into the circulation via gluconeogenesis, uptake of glucose from the circu-
lation, and reabsorption of glucose from glomerular filtrate to conserve glucose carbon [54]. 
The kidney is unable to release glucose through glycogenolysis [55]. Glucose utilization occurs 
predominantly in the renal medulla. These enzymes can take up, phosphorylate, glycolyse, 
and accumulate, but cannot release, free glucose into the circulation. Glucose release is con-
fined to the renal cortex [56]. Cells in the renal cortex possess gluconeogenic enzymes, and 
they can release glucose into circulation [57, 58]. The main precursor for renal glucogenesis is 
lactate [57]. Obtained results revealed that lactate is the most important renal gluconeogenic 
substrate followed by glutamine and glycerol [59]. Renal conversion to glucose of these precur-
sors accounted for ~ 50, 70, and 35%, respectively, of their overall systemic gluconeogenesis 
[57]. After an overnight fast, 20–25% of glucose released into the circulation derives from the 
kidneys [54].
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Renal glucogenesis is chiefly regulated by insulin and adrenaline. Insulin reduces renal glu-
coneogenesis and reduces the availability of gluconeogenic substrates, thus reducing glu-
cose release into circulation [60]. On the other hand, insulin stimulates renal glucose uptake 
[61]. Adrenaline stimulates renal glucogenesis and glucose release and reduces renal glucose 
uptake [60]. It was shown in animal studies that glucagon increases renal glucose release into 
circulation.
With a daily glomerular filtration rate of 180 L, approximately 162 g of glucose must be reab-
sorbed each day to maintain a normal fasting plasma glucose concentration of 5.6 mmol/L 
[62]. Reabsorption of glucose in the proximal tubule is mediated by glucose transporter pro-
teins that are present in cell membranes. SGLTs mediate active transport of glucose. SGLT2, 
which is in the convoluted section on the proximal tubule (S1), is considered most important. 
It is responsible for reabsorbing 90% of the glucose filtered at the glomerulus. SGLT1, which 
is found in the straight section of the proximal tubule (S3), contributes to the other 10% of 
glucose reabsorbed in the proximal tubule [63]. GLUT proteins are expressed at the basolat-
eral membrane of the epithelial cells. These transporters release into circulation the glucose 
reabsorbed by SGLTs in the tubular cells. Glucose reabsorbed by SGLT2 is then released into 
the circulation via GLUT2 and reabsorbed by SGLT1 [64]. In the postabsorptive setting after 
an overnight fast, the kidneys utilize approximately 10% of all glucose utilized by the body. 
After meal ingestion, their glucose utilization increases in absolute sense [54].
7. Role of the hypothalamic-pituitary axis in the glucose homeostasis
The role of the brain to control glucose homeostasis was introduced in 1964 [65, 66]. Energy 
homeostasis is maintained by adapting meal size to current energy requirements. This con-
trol is achieved by communication between the digestive system and central nervous system. 
Two systems regulate the quantity of food intake: short term, which prevents overeating, 
and long term, involved in the energy stores as a fat [67]. Several regions of the brain are 
involved in regulation of food intake and energy homeostasis [68–72]. The hypothalamus is 
the most important locus involved in the neural control peripheral metabolism through the 
modulation of autonomic nervous system activity. The autonomic nervous system modulates 
hormone secretion (insulin and glucagon) and metabolic activity of the liver, adipose tissue, 
and muscle. The hypothalamus is in turn informed of the energy status of the organism. 
This is due to the metabolic and hormonal signals. There are two ways for the hypothala-
mus to signal to the peripheral organs: by stimulating the autonomic nerves and by releas-
ing hormones from the pituitary gland. The hypothalamus consists of three areas: lateral, an 
important region regulating the cessation of feeding [73]; medial; and paraventricular, which 
is involved in the initiation of feeding [74]. In addition to direct neural connections, the hypo-
thalamus can affect metabolic functions by neuroendocrine connections.
In the hypothalamus-pancreas axis, autonomic nerves release glucagon and insulin, which 
directly enter the liver and affect liver metabolism. In the hypothalamus-adrenal axis, auto-
nomic nerves release catecholamines from adrenal medulla, which also affect liver metabo-
lism. The hypothalamus-pituitary axis, which consists of neuroendocrine pathways from the 
Glucose Homeostasis
http://dx.doi.org/10.5772/67222
13
hypothalamus, can also regulate liver functions. The hypothalamus sends signals to the pitu-
itary gland, which release different hormones. Among them, three are thought to be intensely 
involved in the regulation of liver glucose metabolism [75].
The hypothalamic-pituitary-adrenal (HPA) axis referees to a complex set of homeostatic inter-
actions between the hypothalamus, the pituitary gland, and the adrenal gland. The core of 
the HPA axis is the paraventricular nucleus (PVN) of the hypothalamus. The PVN contains 
neurocrine neurons, which synthesize and secrete vasopressin (AVP) and corticotrophin-
releasing hormone (CRH). These two peptides can stimulate the secretion of the adrenocorti-
cotropic hormone (ACTH) from anterior pituitary. In turn, ACTH enters peripheral circulation 
where it reaches the adrenal cortex to induce glucocorticoid hormone production (cortisol). 
Glucocorticoids exert a negative feedback on the paraventricular nucleus of the hypothala-
mus and pituitary to suppress CRH and ACTH production, respectively. Activation of gluco-
corticoids in vivo causes activation of glycogen synthase and inactivation of phosphorylase, 
resulting in glycogen synthesis [76]. Glucocorticoids lead to lipolysis in adipose tissue and pro-
teolysis in the skeletal muscle by inhibiting glucose uptake by these tissues resulting in release 
of glycerol from adipose tissue and amino acids from the muscle [77, 78]. In turn, glycerol and 
amino acids are used as substrates to produce glucose in the liver. Glucocorticoids stimulate 
hepatic gluconeogenesis and antagonize actions of insulin in the liver and muscle, thus tend-
ing to increase glucose levels. The expression of GLUT4 is increased by glucocorticoids in the 
skeletal muscle and adipose tissue. Increased lipolysis may be important in glucocorticoid-
induced insulin resistance. Glucocorticoids inhibit insulin secretion from pancreatic β-cells.
Maintenance of thyroid function is depended on a complex interplay between the hypothal-
amus, anterior pituitary, and thyroid gland (HPT). The thyroid gland is controlled by the 
activity of the hypothalamic-pituitary-thyroid axis. The hypothalamus releases thyrotropin-
releasing hormone (TRH) which stimulates the biosynthesis, and release of thyrotropin (TSH) 
forms the anterior pituitary. TSH stimulates the thyroid gland which releases thyroxine (T4) 
and triiodothyronine (T3) into the circulation. Thyroid hormone action has been long rec-
ognized as a significant determinant of glucose homeostasis [79, 80]. Glucose homeostasis 
appears to be the result of the T3 and insulin synergistic regulation of gene transcription 
involved metabolic pathways of glucose and lipids [81]. T3 regulates a gene expression of 
glucose metabolism (the enzymes for oxidation of glucose and lipids, glucose storage, gly-
colysis, cholesterol synthesis, and glucose-lipid metabolism) [82]. T3 directly stimulates basal 
and insulin-mediated glucose uptake in the rat skeletal muscle. This induction was shown to 
be due primarily to an increase in Glut4 protein expression [83].
Human growth hormone (GH) is an essential regulator of carbohydrate and lipid metabolism. It 
increases indirectly the production of glucose in the liver. Glycerol released into the blood acts as a 
substrate for gluconeogenesis in the liver. GH antagonizes insulin action; increases fasting hepatic 
glucose output, by increasing hepatic gluconeogenesis and glycogenolysis; and decreases periph-
eral glucose utilization through the inhibition of glycogen synthesis and glucose oxidation [84].
The main regulatory factor of reproductive functions is gonadotropin-releasing hormone 
(GnRH), secreted by the hypothalamus. GnRH is a primary stimulator of luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH). In men, LH stimulates testes to synthesis 
and secrete sex hormone, testosterone. In women, FSH acts on the ovary to stimulate and 
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release estrogens. Estrogens are considered in blood glucose homeostasis. Estrogens have an 
adverse effect on carbohydrate metabolism. Administration of estrogens increases the insulin 
content of the pancreas in rats. In β-cells estrogens increase biosynthesis of proinsulin. During 
pregnancy, estrogen receptor integrates information from estrogen, glucose and other nutri-
ents in the blood to regulate insulin gene expression and, therefore, contributes to the main-
tenance of insulin and glucose homeostasis [85]. Estrogen increases expression of glucose 
transporters and glucose transport in blood-brain barrier endothelium. Androgens can influ-
ence body composition, which is associated with insulin sensitivity. Testosterone may affect 
insulin sensitivity. Patients treated with androgen deprivation therapy have elevated glucose 
and increased insulin resistance. Testosterone treatment in hypogonadal men reduces fasting 
insulin. Testosterone activates the glucose metabolism-related signaling pathway in the skel-
etal muscle. The addition of testosterone to the cultured skeletal muscle induces the elevation 
of GLUT4 protein expression and accelerates its translocation from cytosol to plasma mem-
brane. In women, testosterone induces selective insulin resistance in cultured subcutaneous 
adipocytes.
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